Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • Oncotutorial

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]

  • Long Idea of the Year

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. You can see all of his old articles and his most recent comments on his Stock Gumshoe page.] “Keep it quiet. (Go slow.) […]

  • Quickster: Update on Corbus

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He chooses his own topics, and his words and opinions are his own. He has agreed to our trading restrictions. To see all of his column and his latest comments, go to his Stock Gumshoe page.] [Author’s note: This commentary has been […]

  • The 12 Biotechs of Christmas: Six

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

  • The 12 Biotechs of Christmas: Five

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

  • The 12 Biotechs of Christmas: Four

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

  • The Twelve Biotechs of Christmas: Two

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

  • Such A Pleasant Stay

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

  • Sea of Tranquility

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

  • Tropic of Palatin

    [Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

  • Ten Common Biotech Investing Mistakes

    [Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]

  • Quickster: T2 Biosystems ($TTOO)

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page to see his biography, latest comments and past articles.] About 18 months ago, I came across tiny Boston-area diagnostics start-up […]

  • The State of Things: Ruction at Regulus

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

  • Recent Author Comments

    On Oncotutorial
    I sincerely wouldn't touch Kadmon with a 50 foot robotic arm. "Danger Will Robinson! Danger!" I could write a book, well a novella anyway, about the dirt I know on the company. Dirty dirt, too. Poor Adam F....he'll eventually have to block the entire T[...]
    On Oncotutorial
    I'm going to be frank: I should not feel heckled for having mentioned Rice reached out to me. I have no idea what he intends to tell me, as I am not a mind reader. Rice cannot disclose non-public information to me without making an SEC filing, but this is [...]
    On Oncotutorial
    I've had a couple of cheapshots leveled at me over $ONOV, but I love the company, stand by it, have a significant position in it. I felt the agent would work and it has. I felt that Jean Ekobo has the grandeur of conception to bring all this to fruition st[...]
    On Oncotutorial
    Yes, Phil, and I agree with that. I've read criticisms of the 1b trial that are structured thus: the trial is so small, data so limited, how can it be interpreted? Then, those analyses hatchet the uninterpretible data to bits claiming it is favorable on ax[...]
    On Oncotutorial
    Hi Mosley....just got through US Customs and have to fly home yet. I will speak with him this week, possibly tomorrow. I hate talking to CEO's or suchlike people from airports. Thanks for asking.[...]
    On Oncotutorial
    This thread is about biotech, not politics. Next we'll have bachsong braying an ode to Kevetrin for solo cello.[...]
    On Oncotutorial
    The Juan Valdez priapism? I've been drinking Juan for several days, and it's not that export grade filler they send to the US, and I like it.[...]
    On Oncotutorial
    Oh yes, and that's a good point Kucheka. True indeed. The drug DOES cause healthy neural tissue to grow, but that's not to say it's some greengrow agent for the brain. Like the liver, like other tissues, brain seems to have some limited capacity of recogni[...]
    On Oncotutorial
    Hi and thanks for posting. I would caution that really none of these metrics applies in this case. This is a wee-cap, speculative, money-losing start-up whose entire future is contingent on a single issue: does its beta blocker prevent afib in people with [...]
    On Oncotutorial
    One is always cautious getting out in front of a neuroscience play. But I'd like everyone to remember the key thrust of my original formulation at the first mention of $CUR: that positive double-blind placebo controlled data exist and have been published i[...]
    On Oncotutorial
    If share price in $BIOC were to rise, what would that look like? What would be the mechanism? Clinical revenue? Wrong. This industry tends to tolerate perhaps a 5 percent profit margin on tests for the lab doing the tests, though it spavins on retail fees [...]
    On Oncotutorial
    Kucheka: thanks for your post. I think Marianne is right here: price movement today is NOT about data or these I131 studies. My opinion? They are pure potboiler. Not saying I don't love the company or Jim Caruso...I do. This is just them doing something to[...]
    On Oncotutorial
    Poking my head in from far far away to say I appreciate Grant's post above. Honor Roll. It is material I was going to cover in a column I'm writing on the Aptose situation, but obviously nothing's wrong with Grant delving into it; we want everyone in the s[...]
    On Oncotutorial
    My take is that people are accepting that voclosporin and $AUPH are inexorable, like death and taxes. AUPH is coming, is going to make money, and you either invest or get out of the way and shut up. Rarely has any short case been as thin as here. Amazingly[...]
    On Oncotutorial
    This stings and deeply disappoints. You just can't count on the agency to be reasonable. They will be eternally obsessed with two things: blood clots and liver tests. Building a larger database is a redundant exercise, in my view. The issue here is that[...]
    On Oncotutorial
    Phase 2 diabesity trial with 1061 begins enrolling Down Under in 2H17, but protocol STILL not posted. Stock likely to marinade for a while. Long, adding. $ZFGN. #addwhilstcheap?[...]
    On Oncotutorial
    http://www.nature.com/ajg/journal/v105/n1/full/ajg2009505a.html With friends like this, who needs enemas?[...]
    On Oncotutorial
    Infact, during the 1990's, the alternative and complementary medicine crowd were fixated on them, especially enemas made from green coffee. No one could articulate clearly why he such a maneuver might help: more direct absorption of metabolism-inducing or [...]
    On Oncotutorial
    I'm not aware of pre-clinical evidence that CD40 antagonism should work in LN. CD40 is widely distributed in the body and this approach may prove toxic in a way not seen in phase 1. Where tested clinically, CD40 blockade mostly has anti-leukemic/anti multi[...]
    On Oncotutorial
    and not only that but.....! https://www.ncbi.nlm.nih.gov/pubmed/9359807[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.